Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...

Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply ...

Novo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that ...

Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection pens for CagriSema, the former’s ...

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of ...

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including ...

Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat.com reports.

Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy ...